Create
Learn
Share

CC May 2015 Aspirin for primary prevention

rename
echoecho's version from 2015-05-06 16:46

Section

Question Answer
What is the latest statment by the FDA showing declination to approve ASA for primary prevention of cardiovascular disease? "the FDA has reviewed the available data and does not believe the evidence supports the general use of taking aspirin to reduce the possibility ofvhaving a heart attack or stroke.."
What clear distinction did the FDA make regarding ASA?it made a clear distinct between its rejection of ASA for primary prevention and its ENDORSEMENT of ASA for SECONDARY prevention
List the 2 patient population groups that the USPSTF recommends ASA for primary prevention of cardiovascular disease?1. men (45-79 y.o.) if the potential benefit of a reduction in MI outweighs the potential harm of an increase in GI hemorrhage 2. Women (55-79 y.o.) when the potential benefits of a reduction in ischemic stroke outweighs the potential harm of an increase in GI hemorrhage
The USPSTF recommended against ASA for primary prevention in women younger than _____ y.o. and men younger than ____ y.o.? 55; 45
The USPSTF stated that there was insufficient evidence to recommend for or against ASA use in patients > _____ y.o.?80
In 2010, the ACC and ADA and ACCF released a joint statement regarding the use of ASA for primary prevention of cardiovascular disease. It stated that low dose (75-162 mg/d) ASA use for prevention is reasonable for adults with what 3 conditions?1. diabetes 2. no previous hx of vascular disese 3. those who are at increased cardiovascular risk (10 year risk of CVD events > 10%) and who are not at increased risk for bleeding (based on hx of previous GI bleed or PUD or concurrent use of other medications that increase bleeding risk (NSAIDS or Warfarin)
Those adults with diabetes at increased CVD risk include most men over the age of ____ y.o. and women over the age of _____ y.o. who have at least one or more of additional major risk factors (smoking, HTN, dyslipidemia, family hx of premature CVD and albuminuria)?50; 60
In 2010, the ACC and ADA and ACCF released a joint statement regarding the use of ASA for primary prevention of cardiovascular disease. What is the recommendation for a patient with diabetes (men < 50 y.o. and women < 60 y.o.) with no major additional CVD risks factors (smoking, HTN, dyslipidemia, fm hx of premature CVD and albuminuria) and who have 10 year CVD risk < 5%? Why? 1. ASA should be used for CVD prevention in these adults 2. because of the potential adverse effects from bleeding offset the potential benefits
In 2010, the ACC and ADA and ACCF released a joint statement regarding the use of ASA for primary prevention of cardiovascular disease.. Low dose (75-162 mg/d) ASA used for prevention may be considered in what patient?diabetics with intermediate CVD risk (younger patient with 1 or more risk factors (smoking, HTN, dyslipidemia, fm hx of premature CVD and albuminuria) or older patients with no risk factors and for those patients with a 10 year CVD risk of 5-10% until further research is available
***What is the conclusion of the USPSTF recommendations regarding ASA for primary prevention?it is reasonable to assess the overall cardiovascular risk of patients considering primary prevention and to discuss the potential risks and benefits of low-dose ASA therapy for those at higher risk
memorize